IGM Biosciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference
IGM Biosciences, Inc. (Nasdaq: IGMS) to present at 42nd Annual J.P. Morgan Healthcare Conference on January 10, 2024. CEO Fred Schwarzer to discuss the company's progress in developing engineered IgM antibodies. Webcast available on company website.
01/03/2024 - 07:00 AM
MOUNTAIN VIEW, Calif., Jan. 03, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today announced that Fred Schwarzer, Chief Executive Officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024, at 11:15 a.m. PST in San Francisco.
A live webcast of the event will be available on the “Events and Presentations” page in the “Investors” section of the Company’s website at https://investor.igmbio.com/news-and-events/events-and-presentations . A replay of the webcast will be archived on the Company’s website for 30 days following the presentation.
About IGM Biosciences, Inc. www.igmbio.com .
Contact: igmbio@argotpartners.com
What is the date of the 42nd Annual J.P. Morgan Healthcare Conference presentation by IGM Biosciences, Inc. (Nasdaq: IGMS)?
The presentation is scheduled for January 10, 2024.
Who will be presenting at the conference on behalf of IGM Biosciences, Inc. (Nasdaq: IGMS)?
Fred Schwarzer, the Chief Executive Officer, will be presenting.
Where can I watch the live webcast of the presentation by IGM Biosciences, Inc. (Nasdaq: IGMS)?
The live webcast will be available on the 'Events and Presentations' page in the 'Investors' section of the Company’s website at https://investor.igmbio.com/news-and-events/events-and-presentations.
Will there be a replay of the webcast available for the presentation by IGM Biosciences, Inc. (Nasdaq: IGMS)?
Yes, a replay of the webcast will be archived on the Company’s website for 30 days following the presentation.
IGMS Rankings
#5303 Ranked by Stock Gains
IGMS Stock Data
Industry
Pharmaceutical Preparation Manufacturing
Sector
Manufacturing
Tags
Health Technology, Biotechnology, Pharmaceuticals: Major, Manufacturing, Pharmaceutical Preparation Manufacturing
Country
United States
City
Mountain View
About IGMS
igm biosciences, inc., a biotechnology company, engages in the research and development of immunoglobulin m (igm) antibodies for the treatment of cancer. the company's lead product candidate is igm-2323, a bispecific igm antibody that is in phase 1 clinical trials to treat patients with b cell nhl and other b cell malignancies. it is also developing igm-8444, an igm antibody targeting death receptor 5 proteins; and igm-7354, is a bispecific igm antibody delivering interleukin-15 cytokines to pd-l1 expressing cells for use in the treatment of patients with solid and hematologic malignancies. igm biosciences, inc. has a collaboration with atreca inc. and beigene ltd. to discover, develop, and manufacture novel igm and iga antibodies targeting sars-cov-2 for the potential treatment of covid-19; and strategic research collaboration and license agreement with abcellera to discover and develop igm antibodies. the company was formerly known as palingen, inc. and changed its name to igm biosci
